206 related articles for article (PubMed ID: 35210015)
21. Hepatocellular carcinoma: the role of the North American GI Steering Committee Hepatobiliary Task Force and the advent of effective drug therapy.
O'Neil BH; Venook AP
Oncologist; 2007 Dec; 12(12):1425-32. PubMed ID: 18165619
[TBL] [Abstract][Full Text] [Related]
22. Molecular targeted and immune checkpoint therapy for advanced hepatocellular carcinoma.
Liu Z; Lin Y; Zhang J; Zhang Y; Li Y; Liu Z; Li Q; Luo M; Liang R; Ye J
J Exp Clin Cancer Res; 2019 Nov; 38(1):447. PubMed ID: 31684985
[TBL] [Abstract][Full Text] [Related]
23. [New approval: Atezolizumab and bevacizumab for first line of unresecable hepatocellular carcinoma].
Minot-This MS; Edeline J
Bull Cancer; 2021 Feb; 108(2):139-140. PubMed ID: 33546873
[No Abstract] [Full Text] [Related]
24. Hepatocellular carcinoma: the search for innovative adjuvant therapies.
Yen Y; Zhou W
Oncology (Williston Park); 2009 Dec; 23(14):1291, 1294. PubMed ID: 20120843
[No Abstract] [Full Text] [Related]
25. Adjuvant sorafenib for liver cancer: wrong stage, wrong dose.
Kelley RK
Lancet Oncol; 2015 Oct; 16(13):1279-81. PubMed ID: 26433814
[No Abstract] [Full Text] [Related]
26. Advanced hepatocellular carcinoma with response to lenvatinib after atezolizumab plus bevacizumab.
Yano S; Kawaoka T; Johira Y; Miura R; Kosaka M; Shirane Y; Murakami S; Amioka K; Naruto K; Ando Y; Kosaka Y; Yamaoka K; Kodama K; Uchikawa S; Fujino H; Ohno A; Nakahara T; Murakami E; Okamoto W; Yamauchi M; Imamura M; Mori K; Arihiro K; Kuroda S; Kobayashi T; Ohdan H; Aikata H
Medicine (Baltimore); 2021 Oct; 100(42):e27576. PubMed ID: 34678902
[TBL] [Abstract][Full Text] [Related]
27. Contemporary management of hepatocellular carcinoma.
Palmer D
Clin Med (Lond); 2008 Aug; 8(4):442-7. PubMed ID: 18724617
[No Abstract] [Full Text] [Related]
28. Recent Developments and Therapeutic Strategies against Hepatocellular Carcinoma.
Yarchoan M; Agarwal P; Villanueva A; Rao S; Dawson LA; Llovet JM; Finn RS; Groopman JD; El-Serag HB; Monga SP; Wang XW; Karin M; Schwartz RE; Tanabe KK; Roberts LR; Gunaratne PH; Tsung A; Brown KA; Lawrence TS; Salem R; Singal AG; Kim AK; Rabiee A; Resar L; Hoshida Y; He AR; Ghoshal K; Ryan PB; Jaffee EM; Guha C; Mishra L; Coleman CN; Ahmed MM
Cancer Res; 2019 Sep; 79(17):4326-4330. PubMed ID: 31481419
[TBL] [Abstract][Full Text] [Related]
29. Review article: new therapeutic interventions for advanced hepatocellular carcinoma.
Bangaru S; Marrero JA; Singal AG
Aliment Pharmacol Ther; 2020 Jan; 51(1):78-89. PubMed ID: 31747082
[TBL] [Abstract][Full Text] [Related]
30. Adjuvant treatment of hepatocellular carcinoma after orthotopic liver transplantation: do we really need this?
Fujiki M; Aucejo F; Kim R
Clin Transplant; 2013; 27(2):169-77. PubMed ID: 23216662
[TBL] [Abstract][Full Text] [Related]
31. Is Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma Superior Even to Lenvatinib? A Matching-Adjusted Indirect Comparison.
Casadei-Gardini A; Tada T; Shimose S; Kumada T; Niizeki T; Cascinu S; Cucchetti A
Target Oncol; 2021 Mar; 16(2):249-254. PubMed ID: 33638735
[TBL] [Abstract][Full Text] [Related]
32. An update of treatments of hepatocellular carcinoma in patients refractory to sorafenib.
Ielasi L; Sansone V; Granito A; Benevento F; De Lorenzo S; Tovoli F
Drugs Today (Barc); 2018 Oct; 54(10):615-627. PubMed ID: 30398482
[TBL] [Abstract][Full Text] [Related]
33. Sorafenib combined with locoregional therapy prior to liver transplantation for hepatocellular carcinoma: an update on a previous case report.
Vagefi PA; Hirose R
J Gastrointest Cancer; 2013 Jun; 44(2):246-7. PubMed ID: 22815137
[No Abstract] [Full Text] [Related]
34. Systemic therapy of hepatocellular carcinoma: current and promising.
Kalyan A; Nimeiri H; Kulik L
Clin Liver Dis; 2015 May; 19(2):421-32. PubMed ID: 25921671
[TBL] [Abstract][Full Text] [Related]
35. Immune checkpoint inhibitor for hepatocellular carcinoma recurrence after liver transplantation.
Zhuang L; Mou HB; Yu LF; Zhu HK; Yang Z; Liao Q; Zheng SS
Hepatobiliary Pancreat Dis Int; 2020 Feb; 19(1):91-93. PubMed ID: 31706859
[No Abstract] [Full Text] [Related]
36. Real-world systemic sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a multicenter retrospective study in Korea.
Lee MJ; Chang SW; Kim JH; Lee YS; Cho SB; Seo YS; Yim HJ; Hwang SY; Lee HW; Chang Y; Jang JY
Invest New Drugs; 2021 Feb; 39(1):260-268. PubMed ID: 32749658
[TBL] [Abstract][Full Text] [Related]
37. Regorafenib: a newly approved drug for advanced hepatocellular carcinoma.
Kyrochristos ID; Ziogas DE; Roukos DH
Future Oncol; 2017 Aug; 13(19):1665-1668. PubMed ID: 28613123
[No Abstract] [Full Text] [Related]
38. Cabozantinib in combination with atezolizumab versus sorafenib in treatment-naive advanced hepatocellular carcinoma: COSMIC-312 Phase III study design.
Kelley RK; W Oliver J; Hazra S; Benzaghou F; Yau T; Cheng AL; Rimassa L
Future Oncol; 2020 Jul; 16(21):1525-1536. PubMed ID: 32491932
[TBL] [Abstract][Full Text] [Related]
39. The role of sorafenib in hepatocellular carcinoma.
Gholam P
Clin Adv Hematol Oncol; 2015 Apr; 13(4):232-4. PubMed ID: 26352581
[No Abstract] [Full Text] [Related]
40. Systemic treatment for hepatocellular carcinoma.
Ján T; Dáša S; Igor A; Jana V
Klin Onkol; 2020; 33(5):356-361. PubMed ID: 33108880
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
